文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

立体定向放射外科联合或不联合全脑放疗治疗有限脑转移:N0574随机试验二次分析

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-08-05

该研究基于N0574随机试验中126例非小细胞肺癌(NSCLC)脑转移患者,按诊断特异性分级预后评估(DS-GPA)分层分析全脑放疗(WBRT)与总生存的关系。结果显示,在预后良好(DS-GPA≥2.0或≥2.5)患者中,接受WBRT与否的总生存无显著差异,支持对多数有限脑转移患者单用立体定向放射外科(SRS)。

要点

  • NSCLC脑转移患者中,无论DS-GPA≥2.0或≥2.5,加用WBRT均未显著改善总生存。

核心结论

  • 在预后良好的NSCLC脑转移患者中,接受WBRT与否的总生存无显著差异。
  • 本研究进一步支持对多数有限脑转移患者单用SRS的治疗策略。

研究设计与样本

  • N0574随机对照试验的二次分析,患者为1至3个脑转移灶,随机接受SRS或SRS+WBRT。
  • 共纳入126例NSCLC患者,中位随访14.2个月;86.3%的患者可计算DS-GPA评分。

主要发现

  • 50.0%的患者DS-GPA≥2.0,23.0%的患者DS-GPA≥2.5,两组基线预后因素均衡。

关键数值与推荐

  • DS-GPA≥2.0定义为预后良好,≥2.5亦作为预后良好界值进行分析。
  • 主要终点为认知功能下降(原试验),本分析评估总生存。

临床怎么用

  • 对于DS-GPA评分良好的NSCLC有限脑转移患者,可考虑单用SRS而不加WBRT,以避免WBRT相关毒性。
  • DS-GPA评分有助于筛选可能从单用SRS中获益的患者。

局限性

  • 为二次分析,样本量有限(126例),统计效能可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether whole-brain radiation therapy (WBRT) is associated with improved overall survival among non-small cell lung cancer (NSCLC) patients with favorable prognoses at diagnosis. METHODS AND MATERIALS: In the N0574 trial, patients with 1 to 3 brain metastases were randomized to receive stereotactic radiosurgery (SRS) or SRS plus WBRT (SRS + WBRT), with a primary endpoint of cognitive deterioration. We calculated diagnosis-specific graded prognostic assessment (DS-GPA) scores for NSCLC patients and evaluated overall survival according to receipt of WBRT and DS-GPA score using 2 separate cut-points (≥2.0 vs <2.0 and ≥2.5 vs <2.5). RESULTS: A total of 126 NSCLC patients were included for analysis, with median follow-up of 14.2 months. Data for DS-GPA calculation were available for 86.3% of all enrolled NSCLC patients. Overall, 50.0% of patients had DS-GPA score ≥2.0, and 23.0% of patients had DS-GPA scores ≥2.5. The SRS and SRS + WBRT groups were well balanced with regard to prognostic factors. The median survival according to receipt of WBRT was 11.3 months (+WBRT) and 17.9 months (-WBRT) for patients with DS-GPA ≥2.0 (favorable prognoses, P=.63; hazard ratio 0.86; 95% confidence interval 0.47-1.59). Median survival was 3.7 months (+WBRT) and 6.6 months (-WBRT) for patients with DS-GPA <2.0 patients (unfavorable prognoses, P=.85; hazard ratio 0.95; 95% confidence interval 0.56-1.62). Outcomes according to the receipt of WBRT and DS-GPA remained similar utilizing DS-GPA ≥2.5 as a cutoff for favorable prognoses. There was no interaction between the continuum of the DS-GPA groups and WBRT on overall survival (P=.53). CONCLUSIONS: We observed no significant differences in survival according to receipt of WBRT in favorable-prognosis NSCLC patients. This study further supports the approach of SRS alone in the majority of patients with limited brain metastases.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Churilla TM, Ballman KV, Brown PD, et al. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2017. PMID: 28939223. doi:10.1016/j.ijrobp.2017.07.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。